NasdaqCM:CLDXBiotechs
Reassessing Celldex Therapeutics (CLDX) Valuation As Shares Trade At A Discount To DCF Estimates
Why Celldex Therapeutics Stock Is Back on Watch
With no single headline event driving attention today, Celldex Therapeutics (CLDX) is drawing interest as investors reassess a clinical stage pipeline, recent share performance and the company’s current valuation setup.
See our latest analysis for Celldex Therapeutics.
The share price at US$27.38 comes after a mixed stretch, with a modest 7 day share price return of 1.37%, a slightly negative 30 day share price return, and a 1 year total...